Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F
Department of Urology, Technische Universität München, Germany.
J Urol. 1996 Mar;155(3):858-62.
Urokinase type plasminogen activator and its inhibitor plasminogen activator inhibitor are associated with invasion and formation of metastases in tumors. In a prospective study urokinase and plasminogen activator inhibitor-1 content in renal cell cancer and benign renal tissue was correlated with the traditional factors of TNM staging and grading as well as ploidy and actual clinical outcome of the patients.
A total of 152 patients, who underwent transperitoneal tumor nephrectomy for renal cell cancer, was followed for a mean of 23.9 months. Urokinase and plasminogen activator inhibitor-1 from the tumor tissue and corresponding benign renal tissue were quantified from detergent extracted tissue samples (1% triton-X = 100 in TBS) and measured with an enzyme-linked immunosorbent assay.
Urokinase content correlated with the development of distant metastases (log rank 4.32, p = 0.037). Cutoff value was 0.84 ng/mg. A group of 11 patients were considered to be at high risk for metastases (9 events) based on urokinase greater than 0.84 ng/mg., while 94 patients were considered to be at low risk (5 events) with urokinase less than 0.84 ng/mg. Plasminogen activator inhibitor-1 significantly correlated with the prevalence of distant metastases (log rank 5.17, MO, 10.04 versus M1, 23.79, p = 0.02) and the development of new metastases postoperatively (MO, 10.85 versus M1, 27.36, p = 0.001). Cutoff value was 12 ng/mg. protein. A group of 41 patients were considered at high risk for relapse (6) based on plasminogen activator inhibitor-1 greater than 12 ng/mg. protein compared to 55 patients with plasminogen activator inhibitor-1 less than 12 ng/mg. protein with only 1 relapse during followup.
Plasminogen activator inhibitor-1, the specific inhibitor of urokinase is a strong and independent prognostic factor in predicting early relapse of renal cell carcinoma. High and low risk groups for disease-free survival can be discriminated by plasminogen activator inhibitor-1 antigen content in the tumor tissue.
尿激酶型纤溶酶原激活剂及其抑制剂纤溶酶原激活剂抑制剂与肿瘤的侵袭和转移形成相关。在一项前瞻性研究中，肾细胞癌和良性肾组织中的尿激酶和纤溶酶原激活剂抑制剂-1含量与TNM分期和分级的传统因素以及患者的倍性和实际临床结果相关。
共有152例接受肾细胞癌经腹肿瘤肾切除术的患者，平均随访23.9个月。从去污剂提取的组织样本（TBS中1% Triton-X = 100）中对肿瘤组织和相应良性肾组织中的尿激酶和纤溶酶原激活剂抑制剂-1进行定量，并通过酶联免疫吸附测定法进行测量。
尿激酶含量与远处转移的发生相关（对数秩检验4.32，p = 0.037）。临界值为0.84 ng/mg。基于尿激酶大于0.84 ng/mg，一组11例患者被认为有高转移风险（9例转移事件），而94例尿激酶小于0.84 ng/mg的患者被认为是低风险（5例转移事件）。纤溶酶原激活剂抑制剂-1与远处转移的发生率显著相关（对数秩检验5.17，M0为10.04，M1为23.79，p = 0.02）以及术后新转移的发生（M0为|10.85，M1为27.36，p = 0.001）。临界值为12 ng/mg蛋白质。基于纤溶酶原激活剂抑制剂-1大于12 ng/mg蛋白质，一组41例患者被认为有高复发风险（6例复发），相比之下，55例纤溶酶原激活剂抑制剂-1小于12 ng/mg蛋白质的患者在随访期间仅有1例复发。
纤溶酶原激活剂抑制剂-1，尿激酶的特异性抑制剂，是预测肾细胞癌早期复发的一个强大且独立的预后因素。通过肿瘤组织中纤溶酶原激活剂抑制剂-1抗原含量可区分无病生存的高风险和低风险组。
